Breast cancer is the most common form of cancer in women. Modern breast cancer treatments have led to increased survival, but at the same time, increased risk for cardiotoxicity and development of heart failure. In this study, the investigators want to evaluate whether nicotinamide riboside can prevent cancer-related cardiac dysfunction in metastatic breast cancer patients scheduled for anthracycline therapy. Further, the investigators will evaluate change in signs of skeletal muscle injury and functional capacity.
Women with metastatic breast cancer (stage IV breast cancer) scheduled for anthracycline-containing chemotherapy
Eastern Cooperative Oncology Group performance status 0-2
Age <18 years
Acute myocardial infarction within the last three months
Participation in another pharmaceutical clinical trial of an investigational medicinal product (IMP) less than 4 weeks prior to inclusion or use of other investigational drugs within 5 half-lives of enrollment, whichever is longer
Conditions that would affect the participants to comply with the study protocol as psychiatric or mental disorders, alcohol abuse or other substance abuse, suspected poor drug compliance, language barriers
Map coordinates are unavailable for these locations. Locations are shown below instead.
NorwayUniversity Hospital, Akershus
Lead sponsor
ChromaDex, Inc.
Collaborator
Norwegian Cancer Society
Collaborator
Norwegian Breast Cancer Association
Collaborator
Helse Sor-Ost
Collaborator